- Conditions
- Heart Failure, Systolic, Heart Failure, Diastolic
- Interventions
- Automated annotation of the left ventricle through deep learning, Sonographer Measurement of LVEF
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 3,495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 3,333
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
- Conditions
- Moderate-severe Pain
- Interventions
- Ages 7-11, ages 12-17
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 19
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 5 more
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- eXciteOSA
- Device
- Lead sponsor
- Signifier Medical Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Colorado Springs, Colorado • Lehigh Acres, Florida + 4 more
- Conditions
- Cholesterol Absorption
- Interventions
- clinoptilolite
- Dietary Supplement
- Lead sponsor
- Canadian Collaborative Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cumming, Georgia
- Conditions
- Multiple Sclerosis
- Interventions
- BIIB033 (opicinumab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 51
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
- Conditions
- Intracranial Meningioma
- Interventions
- [177Lu]Lu-DOTATATE, Standard of Care treatments
- Drug · Other
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 17
- States / cities
- Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
- Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Interventions
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
- Drug · Biological
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Healthy
- Interventions
- LY4100511 (DC-853), Placebo
- Drug
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- OLA group: Olanzapine, DEX group: Dexamethasone
- Drug
- Lead sponsor
- The Guthrie Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Sayre, Pennsylvania
- Conditions
- Healthy Adult
- Interventions
- Niagen®
- Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 80
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Neuroendocrine Tumors in Lung
- Interventions
- Lanreotide (Autogel formulation), Placebo, Best Supportive Care
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Crohn's Disease
- Interventions
- adalimumab, placebo
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
- Conditions
- Hepatitis C Virus
- Interventions
- Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 22
- States / cities
- Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
- Conditions
- Alzheimer Disease, Alzheimer Disease, Late Onset
- Interventions
- MemorEM 1000
- Device
- Lead sponsor
- NeuroEM Therapeutics, Inc.
- Industry
- Eligibility
- 63 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
- Interventions
- Aquamantys, standard electrocautery (Bovie)
- Device
- Lead sponsor
- Joint Implant Surgeons, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New Albany, Ohio
- Conditions
- Leukemia
- Interventions
- AEG35156
- Drug
- Lead sponsor
- Aegera Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more
- Conditions
- Opioid-Related Disorders, Opiate Dependence
- Interventions
- Buprenorphine/naloxone sublingual tablets, Buprenorphine
- Drug
- Lead sponsor
- Orexo AB
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease
- Interventions
- Placebo, MORF-057
- Drug
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 25
- States / cities
- Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
- Conditions
- Prolonged Labor, Failed Induction, Labor Dystocia
- Interventions
- Oxytocin rest
- Other
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Attention Deficit Hyperactivity Disorder, Dyslexia
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 16
- States / cities
- Irvine, California • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Interventions
- Cabozantinib, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- M5049 dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more